Skip to main content

Important Safety Information 

Hybrid AF Therapy

Hybrid AF Therapy is for the treatment of long-standing persistent atrial fibrillation.

Risk Information
This procedure is not recommended for patients with Barrett’s Esophagitis, presence of left atrial thrombus (clot), a systemic infection, or an active infection local to the surgical site at the time of surgery (i.e. active endocarditis).

Potential procedural complications include, but are not limited to: Pericardial effusion, pericarditis, infection, cardiac tamponade, pulmonary vein stenosis, vessel injury, tissue perforation, excessive bleeding, phrenic nerve injury, left atrial rupture, esophageal fistula, heart attack, new arrhythmias, thromboembolic complication, stroke/TIA/neurologic complication, complete heart block requiring permanent pacemaker implantation, serious skin burn, a buildup of fluid around your lungs, or death.

This information is not comprehensive. Talk to your health care provider to obtain the FDA-approved product labeling or visit AtriCure.com.

Rx only

 

PL-002.A, rel. 04-2021